OBJECTIVES: As the life expectancy for PLHIV approaches that of the general population, health-related quality of life (HRQoL) is an increasing consideration when comparing therapies. The objective of this SLR was to identify HSUVs for individuals with HIV-1, to inform cost-effectiveness modelling. METHODS: A previously-published SLR, Tran et al. (BMC Health Serv Res 2015;15:7) was used to identify studies from January 2000–February 2014. Four electronic databases were searched in June 2015 to identify additional studies published since February 2014. Database searches were supplemented by hand-searching bibliographies of SLRs and economic evaluations, and The Lancet HIV (formerly not indexed in bibliographic databases). Eligible studies reported HSUVs measured by the EQ-5D questionnaire. Studies from resource-limited settings or where all patients had comorbidities not widely relevant to HIV models were excluded. RESULTS: Fifteen of 49 articles from Tran et al. (2015) met the inclusion criteria of this SLR (the remainder used non-EQ-5D measures or were from resource-limited settings). Database searching yielded 1128 records; only one fulfilled this review’s inclusion criteria. Four additional articles were identified through hand-searches. Twenty articles (reporting 14 studies) were therefore included in this SLR. Of the 14 included studies, two compared HSUVs of PLHIV vs. the general population; both reported substantially lower HSUVs for PLHIV (mean [SD] 0.65 [0.28] vs. 0.86 [0.23], p=0.0001; and 0.74 [NR] vs. 0.82 [NR], p<0.0001). Eight studies examined impact of disease severity. Six found that more severe disease was associated with significantly lower HSUVs; two found mixed effects (eg. not significant for CD4+ count but significant for viral load). CONCLUSIONS: HIV-1 infection is associated with a lower HRQoL compared to the general population. However, the specific impact of disease severity on HRQoL is unclear. Due to substantial variation between studies, care is needed when selecting appropriate HSUVs for economic evaluations in HIV-1.